Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 7 |
Immune System Diseases | 3 |
Nervous System Diseases | 1 |
Infectious Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Non-recombinant coagulation factor | 3 |
Blood components | 3 |
Recombinant coagulation factor | 2 |
Enzyme | 1 |
AAV based gene therapy | 1 |
Target |
Mechanism factor IX stimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Nov 2022 |
Target |
Mechanism C1-INH modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date22 Jun 2017 |
Target |
Mechanism F8 stimulants |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date25 May 2016 |
Start Date28 Jun 2024 |
Sponsor / Collaborator |
Start Date01 Jun 2023 |
Sponsor / Collaborator |
Start Date18 Jan 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Albutrepenonacog alfa ( F10 ) | Hemophilia B More | Approved |
Alpha1-proteinase inhibitor(human) (CSL Behring GmbH) ( A1AT ) | Lung Diseases More | Approved |
C1 Esterase Inhibitor (Human) ( C1-INH ) | Hereditary Angioedema More | Approved |
C1 Esterase Inhibitor Subcutaneous (Human) ( C1-INH ) | Hereditary Angioedema More | Approved |
Fibrinogen Concentrate (Human) ( Fibrinogen ) | Hemorrhage More | Approved |